产品中心Cell Resources
联系我们CONTACT US
400-999-210024小时服务热线
产品概述
青霉素-链霉素混合液（Penicillin-Streptomycin Solution）通常也被称为“双抗”，用于预防细胞培养的细菌污染，特别是革兰氏阳性和阴性细菌的污染。而L-谷氨酰胺不仅是细胞的能量来源，还是参与蛋白质合成和核酸代谢的重要物质，L-谷氨酰胺的缺乏会导致细胞生长不良甚至死亡。青霉素-链霉素-谷氨酰胺混合溶液联合使用，既能够预防污染的，也可以补充细胞生长必需的谷氨酰胺。
产品信息
形态 | 液体 |
浓度 | 100× |
规格 | 100mL |
pH | 6.1-6.4 |
溶剂 | 10mM PBS缓冲液（PH 6.2） |
青霉素G钠盐 | 10 kU/mL |
硫酸链霉素 | 10 mg/mL |
L-谷氨酰胺 | 200 mM |
抗菌谱 | 革兰氏阳性菌、阴性菌 |
储存条件 | -5~-20℃，避光 |
运输条件 | 低温 |
有效期 | 12个月 |
注意事项
1、本产品经0.1 μm过滤除菌；
2、使用本产品时应注意无菌操作，避免污染；
3、本产品为浓缩液，请根据需要稀释后使用；
4、不宜长时间放置于室温环境或2-8℃长期保存；
5、2-8℃中解冻后溶液变成乳液状属正常现象，该情况系L-谷氨酰胺受温度影响导致溶解度降低而析出，将该溶液表面用75%酒精擦拭摇匀后放入37℃培养箱30分钟-40分钟可以溶解至澄清透明，最后摇匀使用，使用过程中切忌反复冻融，用量较少时建议分装冻存；
6、本产品仅用于科研或进一步研究使用，不用于诊断和治疗。
参考文献
-
Wuzi Yanzong Pill protects neural tube defects by activating PI3K/Akt signaling pathway (2023-05-21)
作者：Xinliang Wang:1.The Key Research Laboratory of Benefiting Qi for Acting Blood Circulation Method to Treat Multiple Sclerosis of State Administration of Traditional Chinese Medicine/Neurobiology Research Center, Shanxi University of Chinese medicine, Jinzhong, China. ; Chanjuan Yang:1.The Key Research Laboratory of Benefiting Qi for Acting Blood Circulation Method to Treat Multiple Sclerosis of State Administration of Traditional Chinese Medicine/Neurobiology Research Center, Shanxi University of Chinese medicine, Jinzhong, China. ; Yanrong Li:1.The Key Research Laboratory of Benefiting Qi for Acting Blood Circulation Method to Treat Multiple Sclerosis of State Administration of Traditional Chinese Medicine/Neurobiology Research Center, Shanxi University of Chinese medicine, Jinzhong, China. ; Qiang Gong:1.The Key Research Laboratory of Benefiting Qi for Acting Blood Circulation Method to Treat Multiple Sclerosis of State Administration of Traditional Chinese Medicine/Neurobiology Re
期刊：Wuzi Yanzong Pill protects neural tube defects by activating PI3K/Akt signaling pathway
影响因子 ：1.8
引用产品： CHO 细胞 , CHO/dhFr- [CHO-DXB11] 细胞 , IMDM 培养基 , 特级胎牛血清 , 青霉素-链霉素-谷氨酰胺溶液 (100×)
-
NLRP3 augmented resistance to gemcitabine in triple-negative breast cancer cells via EMT/IL-1β/Wnt/β-catenin signaling pathway (2007-00-20)
作者：Qiao Zheng:1.Department of Oncology, Affiliated Hospital of Chengdu University of Traditional Chinese Medicine. No. 39 Twelve Bridges Road, Jinniu District, Chengdu 610072, China. ; Dejiao Yao:1.Department of Oncology, Affiliated Hospital of Chengdu University of Traditional Chinese Medicine. No. 39 Twelve Bridges Road, Jinniu District, Chengdu 610072, China. ; Yi Cai:1.Department of Oncology, Affiliated Hospital of Chengdu University of Traditional Chinese Medicine. No. 39 Twelve Bridges Road, Jinniu District, Chengdu 610072, China. ; Tiecheng Zhou:1.Department of Oncology, Sichuan Integrative Medicine Hospital. No. 51, Fourth Section of Renmin South Road, Chengdu 610041, China. ;
期刊：NLRP3 augmented resistance to gemcitabine in triple-negative breast cancer cells via EMT/IL-1β/Wnt/β-catenin signaling pathway
影响因子 ：4.0
引用产品： DMEM高糖 培养基 , 特级胎牛血清 , 青霉素-链霉素-谷氨酰胺溶液 (100×)
FAQs
Q：{{item.question}}
A：
产品资料
识别码示意图
